Exact Sciences/EXAS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Exact Sciences

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Ticker

EXAS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Madison, United States

Employees

6,550
Website
www.exactsciences.com

Exact Sciences Metrics

BasicAdvanced
$8B
Market cap
-
P/E ratio
-$1.33
EPS
1.26
Beta
-
Dividend rate
$8B
1.26
2.568
2.046
79.104
79.104
-11.98%
-3.15%
-7.76%
3.08
2.53
-7.19
-156.93
15.21%
-54.46%
17.93%
-33.94%

What the Analysts think about Exact Sciences

Analyst Ratings

Majority rating from 23 analysts.
Buy

Exact Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-17.28% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$638M
-1.44%
Net income
-$110M
121.73%
Profit margin
-17.28%
125.00%

Exact Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-
-$0.27
-$0.60
-
Expected
-$0.51
-$0.48
-$0.46
-$0.47
-$0.31
Surprise
-11.68%
-
-41.21%
27.32%
-

Exact Sciences News

AllArticlesVideos

Exact Sciences to Participate in June Investor Conferences

Business Wire·1 month ago

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

Business Wire·1 month ago

Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Exact Sciences stock?

Exact Sciences (EXAS) has a market cap of $8B as of July 04, 2024.

What is the P/E ratio for Exact Sciences stock?

The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of July 04, 2024.

Does Exact Sciences stock pay dividends?

No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Exact Sciences dividend payment date?

Exact Sciences (EXAS) stock does not pay dividends to its shareholders.

What is the beta indicator for Exact Sciences?

Exact Sciences (EXAS) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Exact Sciences stock

Buy or sell Exact Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing